By Fineline Cube 
Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company, announced its launch on September 16, 2025, with an initial $100 million in financing. The funding was led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital.
Pipeline and Focus
Ollin is developing a robust pipeline of clinical and late-stage preclinical programs, all based on validated biologies to address unmet treatment needs in ophthalmology.
Lead Program: OLN324
OLN324, derived from Innovent Biologics (code: IBI324), is a high-potency, high molar dose VEGF/Ang2 bispecific antibody. It is currently in Phase Ib clinical development for patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME).-Fineline Info & Tech